Our Business Development team invites you to contact them to explore your potential development and commercialization applications using our xMAP® technology. Click here to start the conversation now.
了解更多
METHODS Special Issue: To Parse Inflammation, Scientists Pair Multiplex and Single-Molecule Techniques
A hybrid strategy offers the best of both worlds, revealing mechanisms of injury response
In a recent publication, scientists exploring the relationship between systemic inflammation and peripheral muscle injury report the successful combination of bead-based multiplexing with single-molecule counting technology to evaluate the body’s response to exercise. The paper, released in Methods, comes from scientists at the University of North Texas.
Continue Reading >
xMAP Technology makes up the basis of Luminex’s core business. This flexible technology is centered on the use of Luminex xMAP Microspheres.
Watch more videos >
July 31
Luminex Corporation Reports Second Quarter 2019 Financial Results And Increase In Quarterly Dividend
July 11
Luminex Corporation Second Quarter Earnings Release Scheduled for July 31, 2019
July 1
Luminex Submits ARIES MRSA Assay for FDA Clearance
May 21
Luminex Corporation Declares Second Quarter Cash Dividend
May 14
Luminex Corporation to Present at Upcoming Healthcare Investor Conferences
AACC Annual Meeting & Clinical Lab Expo
August 6-8
Anaheim, CA
IDWeek
October 2-6
Washington, D.C.
xMAP® Connect San Diego
October 3
San Diego, CA
